Batbold Boldbaatar's scientific contributions
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (7)
Hepatitis B virus (HBV) is a hepatotropic virus causing hepatitis, cirrhosis and hepatocellular carcinoma (HCC). The methylation status of the HBV DNA in its different forms can potentially provide insight into the pathogenesis of HBV-related liver diseases, including HCC, however this is unclear. The goal of this study is to obtain comprehensive D...
AimAberrant methylation of the promoter, P2, and the first exon, E1, regions of the tumor suppressor gene RASSF1A have been associated with HCC, albeit with poor specificity. This study analyzed the methylation profiles of P1, P2, and E1 regions of the gene to identify the region of which methylation most specifically corresponds to HCC and to eval...
HBV related liver disease ranges from hepatitis, cirrhosis, and hepatocellular carcinoma (HCC), which has a 5-year survival rate of 14% because it is difficult to diagnose at its curative stages. Chronic hepatitis B virus (HBV) infections is the major etiology of HCC, associated with over 50% of HCC cases worldwide and up to 70-80% in endemic areas...
Hepatitis B virus (HBV) is a hepatotropic virus causing hepatitis, cirrhosis and hepatocellular carcinoma. In patients, HBV DNA circulates in blood as virion DNA and exists in hepatocytes both as nuclear form (episomal cccDNA and integrated DNA) and as cytoplasmic core DNA form. It has been reported that HBV infection up-regulates DNMTs and thus in...
Hepatocellular carcinoma (HCC) is an aggressive malignancy that is responsible for between 250,000 and 800,000 deaths annually worldwide. HCC has a poor prognosis with a 5-year survival rate of less than 15% mainly due to a lack of early detection. The current biomarker for HCC is the alpha-fetoprotein (AFP), which has a low sensitivity of 40-60%....
Hepatocellular carcinoma (HCC) is the second fastest growing cancer and one of the top 10 causes of cancer deaths in the United States. The 5-year survival rate is 14%, ranging from 26% among early stage tumors to only 2% in late stage HCC. The only available biomarker for screening, serum alpha-fetoprotein (AFP), has a low sensitivity of detection...
Hypermethylation of the glutathione S-transferase π 1 (GSTP1) gene promoter region has been reported to be a potential biomarker to distinguish hepatocellular carcinoma (HCC) from other liver diseases. However, reports regarding how specific a marker it is have ranged from 100% to 0%. We hypothesized that, to a large extent, the variation of specif...
Citations
... These CpG islands are properly positioned in the regulatory domain of the HBV genome. 127 The ATG start site overlaps with the first CpG island (CpG I) of the short sequence of HBsAg, the enhancers I and II, the core promoter, and the sequence of HBx promoter overlap in the second (CpG II) island, and the SpI promoter overlaps the third (CpG III) island with the ATG start codon of the polymerase gene. 21 In the ten genotypes (A−J) of HBV, CpG I is found in five different genotypes (A, B, D, E, and I); on the other hand, CpG II and III have been reported in all genotypes. ...
... Hepatitis B virus (HBV) infection causes liver diseases, ranging from fulminant hepatitis to cirrhosis, eventually leading to hepatocellular carcinoma (HCC) (Lok and McMahon, 2009;Lin et al., 2014). The viral genome consists of an enveloped nucleocapsid containing a partially double-stranded relaxed circular DNA genome of 3.2 kb (Sato et al., 2015). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/279046538711040-1443541287181_Q64/Timothy-Block-2.jpg)
... (10,11) Recent studies have shown that integrated HBV DNA can be detected in the circulation as well. (12)(13)(14)(15) We have previously demonstrated that urine of patients with HCC contains cell-free DNA (cfDNA) with HCC-associated modifications, (16)(17)(18)(19) whereas urine of patients infected with HBV contains fragmented (but not intact) HBV DNA. (20) We hypothesize that urine can serve as a noninvasive liquid biopsy for the investigation of HBV integration in patients infected with HBV. ...
... For methylation specific PCR method, the number and location of the methylated CpG in the target sequence is crucial in designing primers and probe, which allow improving assay specificity [9,22]. Thus, the methylated status of two CpG rich sequences in the SHOX2 promoter was firstly assessed for 40 FFPE samples including 20 lung cancer and 20 non-cancerous lung diseases. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/406878636003329-1474018834543_Q64/Kung-Chao-Chang.jpg)
